Alda-1 is a potent and selective Aldehyde Dehydrogenase-2 Agonist. Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice. Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice. Alda-1 reduces cerebral ischemia/reperfusion injury in rat through clearance of reactive aldehydes. Pharmacological activation of ALDH2 by Alda-1 reversed alcoholic steatosis and apoptosis through accelerating aldehyde clearance. This study indicates that ALDH2 is a promising molecular target and Alda-1 has therapeutic potential for treating alcoholic liver disease.
CAS Number: 349438-38-6
Molecular Weight: 324.16
Chemical Name: N-(1,3-Benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide
Appearance: Solid Power.
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: Soluble in DMSO
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥360 days if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined.
HS Tariff Code: 382200
How to use
Alda-1 treatment results in a significant decrease of 4-HNE-protein content in the plasma of apoE−/− mice. Alda-1 administration leads to a slight increase in gene expression related to neurogenesis (Nog), mitochondrial biogenesis (CYTB, ND1), and apoptosis (Bax, Gsk3b) in the Hp of apoE−/− mice. Alda-1 administration leads to 2 and 10 differentially expressed proteins in the FCx and Hp of apoE−/− mice, respectively. Alda-1 (1.5 mg/kg, b.w., i.p.) administration significantly increases the climbing time, tends to reduce the immobility time and increases the swimming time of the prenatally stressed rats in the forced swim test. Moreover, treatment of prenatally stressed rats with Alda-1 significantly increases number of entries into the open arms of the maze and the time spent therein, as assessed by elevated plus-maze test. Alda-1 (8.5 mg/kg, i.p.) with glucose significantly lowers 4-HNE and FJB-positive cells in the cerebral cortex of Alda-1-treated rats than in DMSO-treated rats 24 h after glucose administration. Alda-1 (10 mg/kg per day) treatment prevents aldehydic overload, mitochondrial dysfunction and improves ventricular function in post-MI cardiomyopathy rats.
- Stachowicz A, Głombik K, Olszanecki R, Basta-Kaim A, Suski M, Lasoń W, Korbut R. The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda-1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav Immun. 2015 Aug 4. pii: S0889-1591(15)00428-6. doi: 10.1016/j.bbi.2015.08.004. [Epub ahead of print] PubMed PMID: 26254233.
- Ikeda T, Takahashi T, Tsujita M, Kanazawa M, Toriyabe M, Koyama M, Itoh K, Nakada T, Nishizawa M, Shimohata T. Effects of Alda-1, an Aldehyde Dehydrogenase-2 Agonist, on Hypoglycemic Neuronal Death. PLoS One. 2015 Jun 17;10(6):e0128844. doi: 10.1371/journal.pone.0128844. eCollection 2015. PubMed PMID: 26083658; PubMed Central PMCID: PMC4471358.
- Zhong W, Zhang W, Li Q, Xie G, Sun Q, Sun X, Tan X, Sun X, Jia W, Zhou Z. Pharmacological activation of aldehyde dehydrogenase 2 by Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice. J Hepatol. 2015 Jun;62(6):1375-81. doi: 10.1016/j.jhep.2014.12.022. Epub 2014 Dec 24. PubMed PMID: 25543082.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.